MedTrace Logo

Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia

NCT03192488 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-06-16

Study results available
· View outcomes & findings →

Summary

This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec® use can improve exercise performance of active individuals when acutely exposed to altitude. For this project, healthy subjects will perform steady state and progressive work rate exercise, endurance performance time trials, and repeated sprint performance time trials in the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of Cetirizine or a placebo in a repeated measures design.

Conditions

  • Hypoxia, Altitude

Interventions

DRUG

Cetirizine

Cetirizine tablet 10 mg

DRUG

Placebo oral capsule

Gelatin placebo

OTHER

Hypoxia

Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Robert Chapman, PhD · Indiana University School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-31
Primary Completion
2018-06-06
Completion
2018-06-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03192488 on ClinicalTrials.gov